Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Endeavor Health
Endometrial shedding during the menstrual cycle elicits profound changes in neuronal activity and cytokine concentrations producing moderate to severe pelvic pain in more than 20% of reproductive-age women. One out of every five of those women in turn will experience chronic pelvic pain (CPP) which may be in part due to cross-organ neural sensitization.
In this study we will establish whether prophylactic and adequate dosages of naproxen are capable of reducing menstrual pain more than \*\*\* use.
Age
18–45
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Reproductive-age women (age 18-45) with dysmenorrhea
Average menstrual pain ≥ 5/10 (0=no pain and 10=the worst imaginable pain) on at least one day during menses or during withdrawal uterine bleeding from cyclic OCs without painkillers
Menstrual pain in the region between the umbilicus and the perineum, above the level of the inguinal ligament
Indication the participant has attempted to resolve pain by medical means (including NSAIDs and/or OCPs)
You may not be if
Presence of active pelvic or abdominal malignancies (primary or metastatic)
Absence of regular menses (including current pregnancy, recent pregnancy, or active breast feeding)
Active genitourinary infection in the last four weeks
Unable to read or comprehend the informed consent in English
Unwilling to complete study procedures
Presence of hypertension or risk for developing hypertension
Unwillingness to take naproxen and/or placebo
Contradictions to taking naproxen (allergies, kidney disease, anemia, alcoholism, cardiovascular disease, stomach or intestinal ulcer or abnormal liver function)
Formal urological diagnosis such as overactive bladder or bladder pain syndrome.
